Skip to main content

The independent medical news service

Prostate cancer

15-01-2021 | Oncology | News | Article

Prostate cancer radiotherapy regimen may not impact long-term toxicity

Patients with intermediate-to-high-risk localized prostate cancer report similar long-term bowel and urinary symptoms and sexual function whether treated with ultra-hypofractionated radiotherapy or conventional radiotherapy, phase 3 study data show.

14-01-2021 | Oncology | Highlight | Article

Real-world data support efficacy of SABR for extracranial oligometastases

The beneficial survival outcomes and low toxicity associated with stereotactic ablative body radiotherapy in patients with extracranial oligometastases persist in the real-world setting.

08-01-2021 | Oncology | News | Article

PARP inhibitor use associated with MDS, AML risk

The results of a meta-analysis point to a link between PARP inhibitor use and a small increase in the risk for developing myelodysplastic syndrome and acute myeloid leukemia.

06-01-2021 | Oncology | News | Article

Radical prostatectomy delay viable for localized high-risk prostate cancer

US researchers report that men with clinically localized, high-risk prostate cancer are no more likely to experience adverse pathologic outcomes if radical prostatectomy is delayed for up to 6 months rather than occurring within 31–60 days of diagnosis.

23-12-2020 | Oncology | News | Article

FDA announces breast, lung, prostate cancer approvals

Click through to find out more about the approved drugs

07-12-2020 | Oncology | News | Article

Study highlights PSA screening gaps for transgender people

US researchers report a lower uptake of PSA screening by transgender individuals than cisgender straight men.

04-12-2020 | Oncology | News | Article

FDA approves first PSMA-targeted radiotracer

More details about this decision available here

03-12-2020 | Oncology | News | Article

Clinical guidance may impact cancer treatment rates during COVID-19

The number of people initiating systemic cancer therapies fell substantially at the start of the COVID-19 pandemic but then recovered rapidly with the implementation of new treatment guidance, UK study data show.

02-12-2020 | Oncology | News | Article

Androgen receptor inhibitors implicated in fall, fracture risk in prostate cancer

Treatment with androgen receptor inhibitors is associated with an increased risk for falls and fractures in men with prostate cancer, show findings from a meta-analysis.

01-12-2020 | Oncology | News | Article

Vitamin D supplementation may reduce advanced cancer risk

Vitamin D supplementation is associated with a reduced risk for metastatic or fatal cancer, but the benefit appears to be largely restricted to people with normal BMI, shows an analysis of VITAL study data.

26-11-2020 | Oncology | News | Article

Oligometastatic cancer outcomes acceptable with SABR

Stereotactic ablative radiotherapy is associated with “clinically acceptable” rates of toxicity, local control, progression-free survival, and overall survival in people with oligometastatic cancer, meta-analysis data suggest.

23-11-2020 | Oncology | News | Article

CRPC patients with DNA repair gene aberrations may benefit from platinum-based therapies

Platinum-based chemotherapy is active in patients with advanced castration-resistant prostate cancer and DNA repair gene alterations, shows a chart review.

04-11-2020 | Oncology | News | Article

Racial disparities affect prostate cancer active surveillance outcomes

African–American men with low-risk prostate cancer are more likely to experience disease progression while under active surveillance, and subsequently receive definitive treatment, than their non-Hispanic White counterparts, US study data show.

19-10-2020 | Oncology | News | Article

Olaparib recommended for BRCA-mutated metastatic CRPC

Click through to read this EMA update

12-10-2020 | Oncology | News | Article

Studies support early salvage radiotherapy after prostatectomy

Data from the phase 3 RADICALS-RT, RAVES, and GETUG-AFU 17 trials and the ARTISTIC meta-analysis suggest that observation with early salvage radiotherapy should be the standard of care for men undergoing radical prostatectomy for localized or locally advanced prostate cancer.

08-10-2020 | Oncology | News | Article

Combining ipatasertib with abiraterone may benefit some mCRPC patients

Dual pathway inhibition with the AKT inhibitor ipatasertib plus the androgen receptor inhibitor abiraterone may benefit certain patients with treatment-naïve, metastatic castration-resistant prostate cancer, phase 3 IPATential150 trial data suggest.

10-09-2020 | Oncology | News | Article

Post-radiotherapy ipilimumab shows long-term survival benefits in mCRPC

Men with metastatic castration-resistant prostate cancer who receive ipilimumab after radiotherapy to bone metastases have a significantly better long-term survival rate than those who receive placebo, study findings indicate.

04-09-2020 | Oncology | News | Article

Rucaparib has ‘meaningful’ antitumor activity in BRCA-mutated mCRPC

Phase 2 TRITON2 study data suggest that men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 mutation may benefit from treatment with the PARP inhibitor rucaparib.

19-08-2020 | Oncology | News | Article

Radiotherapy delays may not adversely affect prostate cancer OS

Starting radiotherapy up to 6 months after androgen deprivation therapy may be feasible for men with intermediate- and high-risk localized prostate cancer, say US researchers who found that overall survival was comparable regardless of the timing of radiotherapy initiation.

07-08-2020 | Oncology | News | Article

Neoadjuvant chemohormonal therapy not yet encouraged for localized prostate cancer

The use of chemohormonal therapy before radical prostatectomy does not significantly improve 3-year biochemical recurrence-free survival in men with localized, high-risk prostate cancer, phase 3 trial findings suggest.

Image Credits